RxSight, Inc.
RXST
$6.26
-$0.23-3.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.89% | 10.75% | 27.68% | 46.69% | 57.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.89% | 10.75% | 27.68% | 46.69% | 57.08% |
| Cost of Revenue | -23.21% | -12.18% | 1.74% | 12.72% | 16.06% |
| Gross Profit | 4.11% | 21.32% | 40.89% | 66.32% | 84.03% |
| SG&A Expenses | 10.97% | 19.95% | 26.77% | 30.38% | 35.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.33% | 12.07% | 20.34% | 24.48% | 27.03% |
| Operating Income | -30.75% | -16.38% | -0.39% | 22.66% | 26.41% |
| Income Before Tax | -41.87% | -16.25% | 12.45% | 40.44% | 43.60% |
| Income Tax Expenses | 30.00% | 260.00% | 294.74% | 103.45% | 150.00% |
| Earnings from Continuing Operations | -41.85% | -16.41% | 12.29% | 40.34% | 43.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.85% | -16.41% | 12.29% | 40.34% | 43.52% |
| EBIT | -30.75% | -16.38% | -0.39% | 22.66% | 26.41% |
| EBITDA | -34.99% | -21.68% | -2.65% | 22.56% | 27.66% |
| EPS Basic | -34.00% | -7.15% | 20.87% | 46.68% | 49.93% |
| Normalized Basic EPS | -33.99% | -7.01% | 17.78% | 44.55% | 48.18% |
| EPS Diluted | -34.00% | -7.15% | 20.87% | 46.68% | 49.93% |
| Normalized Diluted EPS | -33.99% | -7.01% | 17.78% | 44.55% | 48.18% |
| Average Basic Shares Outstanding | 5.11% | 7.63% | 9.85% | 11.29% | 12.84% |
| Average Diluted Shares Outstanding | 5.11% | 7.63% | 9.85% | 11.29% | 12.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |